RxDoctor Payments Data

Victoria Carroll

Psychiatric/Mental Health · Memphis, TNNPI 1427501857

Payments from drug & device makers

$5,455in general payments, 2019–2025

Across 299 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Vanda Pharmaceuticals Inc.$575
  • Supernus Pharmaceuticals, Inc.$521
  • Otsuka America Pharmaceutical, Inc.$446
  • AbbVie$425
  • Lundbeck LLC$375
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$5,446100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,455 in reported general payments places this provider in the 90th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$38,161
Medicare patients
33
Services billed
439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl31$44,373
MounjaroTirzepatide29$32,581
TrintellixVortioxetine Hydrobromide42$25,943
UbrelvyUbrogepant13$19,419
FanaptIloperidone13$15,401
Duloxetine Hcl59$2,329
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine55$1,420
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine20$827
Quetiapine Fumarate61$793
Mirtazapine29$600
Divalproex Sodium14$595
Hydroxyzine Pamoate53$588
Alprazolam125$552
Aripiprazole26$540
Lamotrigine52$502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Ubrelvy$425$63,79244 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,038$25,94342 claims
Vanda Pharmaceuticals Inc.Fanapt$575$15,40113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →